The nation of Zimbabwe has declined a substantial US healthcare agreement valued at $367m (272 million pounds) spanning five years due to the United States' demand for sensitive information.
This move became public following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
An official representative has since clarified that the United States was seeking health data for research and profit but was not willing to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued negotiations to secure a agreement agreeable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a similar case in Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to boost openness and responsibility.
Based on reports, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," he stated.
"In essence, our country would supply the raw materials for medical research without any assurance that the end products would be available to our citizens if a future pandemic emerge."
National Interest and Global Health
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending systems already established via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This system is designed to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to continued discussions with our US partners on how subsequent co-operation could be arranged in a way that respects the independence and dignity of both nations."
Medical Community Response
Medical experts said it recognised the official position, but recommended that talks need to persist since much of the nation's Aids initiatives relied on international support.
"Where specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it commented.
The situation emphasises the ongoing challenges between receiving much-needed foreign assistance and protecting a country's data in an increasingly interconnected world.